Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER
Biomarkers, Tumor
/ metabolism
Breast Neoplasms
/ drug therapy
Cell Proliferation
Double-Blind Method
Estrogen Receptor alpha
/ metabolism
Female
Humans
Ki-67 Antigen
/ metabolism
Middle Aged
Protein Kinase Inhibitors
/ pharmacokinetics
Proto-Oncogene Proteins c-akt
/ antagonists & inhibitors
Pyrimidines
/ pharmacokinetics
Pyrroles
/ pharmacokinetics
Signal Transduction
Tissue Distribution
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 04 2020
01 04 2020
Historique:
received:
18
09
2019
revised:
22
11
2019
accepted:
10
12
2019
pubmed:
15
12
2019
medline:
23
1
2021
entrez:
15
12
2019
Statut:
ppublish
Résumé
The STAKT study examined short-term exposure (4.5 days) to the oral selective pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its therapeutic target in sufficient concentration to significantly modulate key biomarkers of the AKT pathway and tumor proliferation. STAKT was a two-stage, double-blind, randomized, placebo-controlled, "window-of-opportunity" study in patients with newly diagnosed ER After 4.5 days' exposure, capivasertib 480 mg b.i.d. ( Capivasertib 480 mg b.i.d. rapidly modulates key biomarkers of the AKT pathway and decreases proliferation marker Ki67, suggesting future potential as an effective therapy in AKT-dependent breast cancers.
Identifiants
pubmed: 31836609
pii: 1078-0432.CCR-19-3053
doi: 10.1158/1078-0432.CCR-19-3053
doi:
Substances chimiques
Biomarkers, Tumor
0
ESR1 protein, human
0
Estrogen Receptor alpha
0
Ki-67 Antigen
0
MKI67 protein, human
0
Protein Kinase Inhibitors
0
Pyrimidines
0
Pyrroles
0
AKT1 protein, human
EC 2.7.11.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
capivasertib
WFR23M21IE
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1574-1585Subventions
Organisme : Cancer Research UK
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
©2019 American Association for Cancer Research.